Syndax Pharmaceuticals (SNDX) Receivables (2023 - 2026)

Syndax Pharmaceuticals' Receivables history runs 4 years deep, the most recent figure standing at $62.8 million for Q1 2026.

• In Q1 2026, Receivables rose 225.1% year-over-year to $62.8 million; the TTM figure through Mar 2026 stood at $62.8 million (up 225.1% YoY), while the FY2025 annual figure was $66.1 million, up 642.48% from the prior year.
• Receivables was $62.8 million for Q1 2026 at Syndax Pharmaceuticals, up from $44.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $62.8 million in Q1 2026 to a low of $1.2 million in Q4 2023.
• Historically, Receivables has averaged $31.6 million across 4 years, with a median of $36.1 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Receivables soared 815.81% in 2024, then surged 225.1% in 2026.
• A 4-year view of Receivables shows it stood at $1.2 million in 2023, then jumped by 815.81% to $11.2 million in 2024, then soared by 295.12% to $44.4 million in 2025, then jumped by 41.48% to $62.8 million in 2026.
• The last three Receivables figures came in at $62.8 million (Q1 2026), $44.4 million (Q4 2025), and $46.3 million (Q3 2025), per Business Quant data.